Terms: = Prostate cancer AND PER1, O15534, 5187, ENSG00000179094, RIGUI AND Treatment
10 results:
1. "Time" for obesity-related cancer: The role of the circadian rhythm in cancer pathogenesis and treatment.
Miro C; Docimo A; Barrea L; Verde L; Cernea S; Sojat AS; Marina LV; Docimo G; Colao A; Dentice M; Muscogiuri G
Semin Cancer Biol; 2023 Jun; 91():99-109. PubMed ID: 36893964
[TBL] [Abstract] [Full Text] [Related]
2. Patterns of treatment failure in patients with prostate cancer treated with 76-80 Gy radiotherapy to the prostate and seminal vesicles ± hormonotherapy.
López-Torrecilla J; Pastor-Peidro J; Vicedo-González A; González-Sanchis D; Hernandez-Machancoses A; Almendros-Blanco P; García-Miragall E; Gordo-Partearroyo JC; García-Hernández T; Brualla-González L; Granero-Cabañero D; Rosello-Ferrando J
Clin Transl Oncol; 2021 Mar; 23(3):481-490. PubMed ID: 32621208
[TBL] [Abstract] [Full Text] [Related]
3. Optimising Radium 223 Therapy for Metastatic Castration-Resistant prostate cancer -5-year Real-World Outcome: Focusing on treatment Sequence and Quality of Life.
Jiang XY; Atkinson S; Pearson R; Leaning D; Cumming S; Burns A; Azzabi A; Frew J; McMenemin R; Pedley ID
Clin Oncol (R Coll Radiol); 2020 Oct; 32(10):e177-e187. PubMed ID: 32448724
[TBL] [Abstract] [Full Text] [Related]
4. [Intravenous vinorelbine as first line chemotherapy in patients with castration-resistant prostate cancer].
Grenader T; Plotkin Y; Rosengarten O
Harefuah; 2014 Dec; 153(12):731-4, 752. PubMed ID: 25654915
[TBL] [Abstract] [Full Text] [Related]
5. Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer.
Mohile SG; Lacy M; Rodin M; Bylow K; Dale W; Meager MR; Stadler WM
Crit Rev Oncol Hematol; 2010 Aug; 75(2):152-9. PubMed ID: 20656210
[TBL] [Abstract] [Full Text] [Related]
6. Efficacy and safety of single-session argon plasma coagulation in the management of chronic radiation proctitis.
Swan MP; Moore GT; Sievert W; Devonshire DA
Gastrointest Endosc; 2010 Jul; 72(1):150-4. PubMed ID: 20493484
[TBL] [Abstract] [Full Text] [Related]
7. Retrospective study of 101 cases with incidental prostate cancer stages T1a and T1b.
Masue N; Deguchi T; Nakano M; Ehara H; Uno H; Takahashi Y
Int J Urol; 2005 Dec; 12(12):1045-9. PubMed ID: 16409608
[TBL] [Abstract] [Full Text] [Related]
8. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959
[TBL] [Abstract] [Full Text] [Related]
9. Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients.
Rodrigues P; Hering F; Campagnari JC
Prostate Cancer Prostatic Dis; 2004; 7(4):350-4. PubMed ID: 15534620
[TBL] [Abstract] [Full Text] [Related]
10. High-dose radiotherapy plus prolonged hormone therapy in CT2-3 prostatic carcinoma: is it useful?
Cellini N; Pompei L; Fortuna G; Ammaturo MV; De Paula U; Luzi S; Mattiucci GC; Morganti AG; Digesù C; Rosetto ME; Palloni T; Petrongari MG; Gentile P; Deodato F; Valentini V
Tumori; 2004; 90(2):201-7. PubMed ID: 15237583
[TBL] [Abstract] [Full Text] [Related]
